OLEMA PHARMACEUTICALS INC (OLMA) Stock Price, Quote, News and Overview
NASDAQ:OLMA - Nasdaq - US68062P1066 - Common Stock - Currency: USD
OLMA Quote, Performance and Key Statistics
4.8
+0.09 (+1.91%)
The current stock price of OLMA is 4.8 USD. In the past month the price increased by 1.05%. In the past year, price decreased by -47.02%.
OLMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.08 | 328.52B | ||
| AMGN | AMGEN INC | 13.29 | 148.31B | ||
| GILD | GILEAD SCIENCES INC | 13.72 | 132.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.46 | 64.41B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.97B | ||
| ARGX | ARGENX SE - ADR | 98.48 | 35.30B | ||
| ONC | BEIGENE LTD-ADR | 5.8 | 25.15B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.51B | ||
| NTRA | NATERA INC | N/A | 20.84B | ||
| BIIB | BIOGEN INC | 8.18 | 18.97B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.83B |
Related stock screener links
About OLMA
Company Profile
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 96 full-time employees. The company went IPO on 2020-11-19. The firm is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. The company is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
Company Info
OLEMA PHARMACEUTICALS INC
780 Brannan Street
San Francisco CALIFORNIA 94107 US
CEO: Sean Bohen
Employees: 85
Phone: 14156513316
OLEMA PHARMACEUTICALS INC / OLMA FAQ
What is the stock price of OLEMA PHARMACEUTICALS INC today?
The current stock price of OLMA is 4.8 USD. The price increased by 1.91% in the last trading session.
What is the ticker symbol for OLEMA PHARMACEUTICALS INC stock?
The exchange symbol of OLEMA PHARMACEUTICALS INC is OLMA and it is listed on the Nasdaq exchange.
On which exchange is OLMA stock listed?
OLMA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OLEMA PHARMACEUTICALS INC stock?
14 analysts have analysed OLMA and the average price target is 26.93 USD. This implies a price increase of 461% is expected in the next year compared to the current price of 4.8. Check the OLEMA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OLEMA PHARMACEUTICALS INC worth?
OLEMA PHARMACEUTICALS INC (OLMA) has a market capitalization of 328.13M USD. This makes OLMA a Small Cap stock.
How many employees does OLEMA PHARMACEUTICALS INC have?
OLEMA PHARMACEUTICALS INC (OLMA) currently has 85 employees.
What are the support and resistance levels for OLEMA PHARMACEUTICALS INC (OLMA) stock?
OLEMA PHARMACEUTICALS INC (OLMA) has a support level at 4.67 and a resistance level at 4.81. Check the full technical report for a detailed analysis of OLMA support and resistance levels.
Should I buy OLEMA PHARMACEUTICALS INC (OLMA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OLMA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OLMA, evaluating the profitability, health, valuation and growth aspects
- OLEMA PHARMACEUTICALS INC (OLMA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OLEMA PHARMACEUTICALS INC (OLMA) Sales and EPS estimates to see what analysts future expectations are.
- OLEMA PHARMACEUTICALS INC (OLMA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OLEMA PHARMACEUTICALS INC (OLMA) Insider and Institutional Ownership to learn about the owners and their transactions.
- OLEMA PHARMACEUTICALS INC (OLMA) Stock Chart to make your own analysis
- OLEMA PHARMACEUTICALS INC (OLMA) Latest news and press-releases to stay up to date.
Does OLEMA PHARMACEUTICALS INC (OLMA) stock pay dividends?
OLMA does not pay a dividend.
When does OLEMA PHARMACEUTICALS INC (OLMA) report earnings?
OLEMA PHARMACEUTICALS INC (OLMA) will report earnings on 2025-08-04.
What is the Price/Earnings (PE) ratio of OLEMA PHARMACEUTICALS INC (OLMA)?
OLEMA PHARMACEUTICALS INC (OLMA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.01).
What is the Short Interest ratio of OLEMA PHARMACEUTICALS INC (OLMA) stock?
The outstanding short interest for OLEMA PHARMACEUTICALS INC (OLMA) is 8.29% of its float. Check the ownership tab for more information on the OLMA short interest.
OLMA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to OLMA. When comparing the yearly performance of all stocks, OLMA is a bad performer in the overall market: 84.95% of all stocks are doing better.
OLMA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OLMA. While OLMA has a great health rating, there are worries on its profitability.
OLMA Financial Highlights
Over the last trailing twelve months OLMA reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS increased by 0.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.71% | ||
| ROE | -31.66% | ||
| Debt/Equity | 0 |
OLMA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to OLMA. The Buy consensus is the average rating of analysts ratings from 14 analysts.